CLINICAL TRIALS PROFILE FOR NEXIUM

505(b)(2) Clinical Trials for NEXIUM

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).

All Clinical Trials for NEXIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	American Lung Association Asthma Clinical Research Centers	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00123656 ↗	Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis	Completed	American Society for Gastrointestinal Endoscopy	Phase 2	2004-08-01	Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be related to both allergies and acid reflux. There have been reports that both swallowed, aerosolized steroids and proton pump inhibitors have been effective treatments. The researchers propose to directly compare the efficacy of aerosolized fluticasone to esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks, subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires (dysphagia, gastroesophageal reflux disease [GERD], and allergy) will be completed by the patient at the first endoscopy and at the end endoscopy. The primary objective is to measure change in eosinophil infiltration of the esophagus in response to treatment of allergy (swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.

Clinical Trial Conditions for NEXIUM

Condition Name

Condition Name for NEXIUM
Intervention	Trials
GERD	16
Gastroesophageal Reflux Disease	15
Healthy	15
Helicobacter Pylori Infection	13

Condition MeSH

Condition MeSH for NEXIUM
Intervention	Trials
Gastroesophageal Reflux	47
Esophagitis, Peptic	19
Dyspepsia	14
Esophagitis	13

Clinical Trial Locations for NEXIUM

Trials by Country

Trials by Country for NEXIUM
Location	Trials
United States	163
Japan	57
Canada	41
Italy	29
Germany	24

Trials by US State

Trials by US State for NEXIUM
Location	Trials
California	11
Texas	11
Florida	8
Pennsylvania	8
New York	8

Clinical Trial Progress for NEXIUM

Clinical Trial Phase

Clinical Trial Phase for NEXIUM
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	2
Phase 4	61

Clinical Trial Status

Clinical Trial Status for NEXIUM
Clinical Trial Phase	Trials
Completed	118
Unknown status	14
Terminated	8

Clinical Trial Sponsors for NEXIUM

Sponsor Name

Sponsor Name for NEXIUM
Sponsor	Trials
AstraZeneca	65
Chinese University of Hong Kong	5
HK inno.N Corporation	5

Sponsor Type

Sponsor Type for NEXIUM
Sponsor	Trials
Industry	118
Other	106
U.S. Fed	4

NEXIUM Market Analysis and Financial Projection

Last updated: April 27, 2026

What do recent clinical and market signals say for NEXIUM (esomeprazole)?

NEXIUM is the brand name for esomeprazole (a proton pump inhibitor, or PPI) with a long commercial history and broad coverage by generic manufacturers in most developed markets. Publicly available patent status and trial activity typically show limited innovation on the original molecule, with most near-term value tied to line extensions, formulation updates, and regional brand-share execution rather than new active clinical breakthroughs.

This brief delivers a clinical-trials snapshot, market reality check, and a forward projection framing for investment and R&D decisions focused on esomeprazole under the NEXIUM label.

---

What is the clinical-trials landscape for NEXIUM (esomeprazole)?

Trial volume and typical focus

Esomeprazole trials globally skew toward:

• Efficacy/safety comparisons vs other PPIs in GERD and erosive esophagitis
• Symptom control endpoints (heartburn, regurgitation) with patient-reported outcomes
• Dosing regimen comparisons (timing relative to meals; once vs twice daily in specific subpopulations)
• Switching studies between formulations and equivalence work for generics/authorized brands
• Special populations (elderly, hepatic impairment, pediatrics) where label language and pharmacokinetics matter more than novel mechanism claims

Signal strength for “newness”

For a marketed PPI whose core mechanism and prescribing landscape are mature, most publicly visible trials tend to be:

• Bridging/bioequivalence or comparator studies
• Short duration maintenance or symptom relief studies
• Regulatory package support tied to specific formulations

The practical implication for R&D is that the “clinical pipeline” for NEXIUM is usually not a traditional innovation pipeline (new molecule, new target, new differentiated MoA). It is often incremental evidence generation around use patterns, formulation, and regulatory compliance.

Evidence expectations for decision-making

A generic-dominated market compresses the commercial payoff from incremental trials. For NEXIUM-branded assets, clinical impact usually depends on one of these outcomes:

• Evidence that a branded formulation improves adherence or real-world persistence
• Demonstrated differentiation for a specific subgroup or dosing schedule
• Payer-preferred positioning enabled by outcomes data that supports reimbursement

Absent a clear platform- or differentiation-enabling development track, clinical trial updates are unlikely to change the pricing and volume curve materially.

---

What does market data say about NEXIUM today (brand vs generic dynamics)?

Market structure

NEXIUM sells into a therapeutic class (PPIs) where:

• Patent exclusivity for esomeprazole (active ingredient) has long expired in key markets
• Generic PPIs drive the majority of volume in most countries
• The remaining branded share depends on:
  • contracted payer formularies
  • wholesaler execution
  • patient switching dynamics
  • brand-specific tolerability narratives and pharmacist preference

Competitive set

The relevant competitive set for esomeprazole is the broader PPI cohort:

• Omeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• Dexlansoprazole

Generic substitution is the default path for PPIs, so brand profitability hinges on net price and rebates rather than on protected monopoly pricing.

What this means for near-term market growth

A mature class with broad generic penetration typically produces:

• Stable or modest growth driven by:
  • population aging
  • GERD prevalence trends
  • health system prescribing volume
• Limited brand upside unless there is:
  • payer-specific branded preference
  • clear superiority in patient outcomes that affects adherence
  • a formulation or dosing strategy that is payer-aligned

---

How should investors and business planners project NEXIUM demand over the next 3 to 7 years?

Projection logic (class-level vs brand-level)

Projection should split into two layers:

1) Therapeutic class volume (PPI market)

• Determined by prevalence and treatment rates for GERD, erosive esophagitis, ulcer prophylaxis, and related indications.

2) Branded share and net price (NEXIUM-specific)

• Determined by generic penetration intensity, payer contracting, and substitution rates.

For NEXIUM, the most decision-relevant variable is branded net revenue per prescription after rebates and discounts, not absolute class growth.

Base-case demand projection framework

Given mature commercialization and generic competition, base-case expectations for branded NEXIUM typically follow this pattern:

• Volume: flat to low single-digit growth at most, driven by class growth and residual brand switching resistance
• Net revenue: pressured by ongoing generic price competition and formulary leakage risk
• Market share: range-bound unless a differentiation event occurs

What would change the trajectory

Branded economics improve if any of the following occurs:

• a formulation is granted formulary preference
• evidence is adopted into clinical guidelines emphasizing esomeprazole specifically for a subgroup
• a payer program reduces copays or improves coverage for branded esomeprazole

Absent those, the curve trends toward:

• share dilution under generic substitution
• price convergence across PPIs

---

What clinical and regulatory milestones matter most for NEXIUM in practice?

1) Indication coverage and guideline uptake

For NEXIUM, the highest leverage is not new phase efficacy. It is:

• maintaining labeled indications across regions
• staying consistent with guideline positioning for GERD/ulcer prevention

2) Formulation and dosing adjustments

Incremental development that can still affect brand value:

• improved patient adherence profiles (if clinically and payer-relevant)
• dosage form changes that reduce barriers (packaging, dosing schedule alignment)

3) Pediatric, renal/hepatic, and long-term safety language

PPIs face sustained scrutiny on long-term safety. Updates that tighten or refine:

• magnesium or nutrient-related monitoring language
• infection risk discussions
• fracture risk statements
  can affect prescribing behavior and market mix without changing the core drug.

---

Where does value concentrate for NEXIUM now: clinical differentiation or commercial execution?

Clinical differentiation (what it must achieve)

To defend brand economics against generics, any clinical update must translate into at least one of these:

• reduces treatment failure rates (symptom persistence)
• improves adherence/persistence (less discontinuation or rescue medication use)
• changes payer posture through outcome-backed coverage decisions

Most typical comparator studies in mature PPIs do not meet these thresholds unless they demonstrate a meaningful patient-centered outcome difference.

Commercial execution (what it usually drives)

For a branded PPI in generic conditions, the dominant drivers are:

• formulary placement and tier status
• rebate and rebate rule compliance
• channel contracting (pharmacy benefit manager and wholesaler dynamics)
• pharmacist substitution protocols and store-level incentives

---

Actionable takeaways for R&D and investment decisions

Key Takeaways

• NEXIUM’s clinical-trial signal in a mature PPI class typically centers on incremental comparator, bridging, and formulation evidence rather than new mechanism-driven innovation.
• Brand performance is primarily a function of net price and branded share under generic substitution, not of new phase efficacy breakthroughs.
• A credible projection treats class volume as the main growth engine and brand economics as a function of payer contracting and formulary dynamics.
• For NEXIUM to outperform the base-case, development and evidence generation must tie directly to payer-relevant differentiation (coverage, adherence, outcomes), not only to standard efficacy endpoints.

---

FAQs

1) Is NEXIUM still facing meaningful clinical innovation competition?

NEXIUM competes within a mature PPI landscape where most clinical updates are incremental. The main competitive pressure is generic substitution rather than lack of efficacy.

2) What endpoints matter most for a branded PPI in generics?

Payer and real-world acceptance typically reward endpoints tied to persistent symptom control, reduced rescue use, and adherence-related outcomes.

3) Does new trial data typically increase NEXIUM market share?

Not unless trial results drive guideline or payer behavior changes that reduce substitution or improve coverage.

4) What drives NEXIUM revenue more: volume or price?

In generic-dominated classes, net price (after rebates/discounts) and branded share changes drive revenue more than prescription count alone.

5) What is the most likely base-case projection?

Flat to low single-digit volume growth with net revenue pressure from generic price competition, unless formulary position improves through differentiated evidence or contracting.

---

References

[1] U.S. Food and Drug Administration. Nexium (esomeprazole magnesium) prescribing information and label history. (Accessed via FDA Drugs@FDA).
[2] National Library of Medicine. ClinicalTrials.gov records for “esomeprazole” and “NEXIUM” (trial results and study types). (Accessed via ClinicalTrials.gov).
[3] GlobalData / IQVIA market intelligence summaries for proton pump inhibitors and branded share trends (PPI class market context).
[4] American College of Gastroenterology (ACG) Clinical Guidelines for GERD (for guideline positioning of PPI therapies).